ATE507215T1 - Verbesserte synthese und zubereitungen von duloxetinsalzen - Google Patents

Verbesserte synthese und zubereitungen von duloxetinsalzen

Info

Publication number
ATE507215T1
ATE507215T1 AT06850470T AT06850470T ATE507215T1 AT E507215 T1 ATE507215 T1 AT E507215T1 AT 06850470 T AT06850470 T AT 06850470T AT 06850470 T AT06850470 T AT 06850470T AT E507215 T1 ATE507215 T1 AT E507215T1
Authority
AT
Austria
Prior art keywords
preparations
improved synthesis
duloxetine
salts
duloxetine salts
Prior art date
Application number
AT06850470T
Other languages
English (en)
Inventor
Stephen Winter
Original Assignee
Medichem Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38437735&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE507215(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medichem Sa filed Critical Medichem Sa
Application granted granted Critical
Publication of ATE507215T1 publication Critical patent/ATE507215T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
    • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AT06850470T 2005-12-12 2006-12-12 Verbesserte synthese und zubereitungen von duloxetinsalzen ATE507215T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US74909505P 2005-12-12 2005-12-12
US74909605P 2005-12-12 2005-12-12
US74909705P 2005-12-12 2005-12-12
US81585406P 2006-06-23 2006-06-23
US81585606P 2006-06-23 2006-06-23
US81583506P 2006-06-23 2006-06-23
PCT/IB2006/004250 WO2007119114A2 (en) 2005-12-12 2006-12-12 Improved synthesis and preparations of duloxetine salts

Publications (1)

Publication Number Publication Date
ATE507215T1 true ATE507215T1 (de) 2011-05-15

Family

ID=38437735

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06850470T ATE507215T1 (de) 2005-12-12 2006-12-12 Verbesserte synthese und zubereitungen von duloxetinsalzen

Country Status (9)

Country Link
US (4) US20090221668A1 (de)
EP (3) EP1971592B1 (de)
AR (1) AR058321A1 (de)
AT (1) ATE507215T1 (de)
CA (3) CA2634007A1 (de)
DE (1) DE602006021628D1 (de)
IL (3) IL192116A0 (de)
PL (1) PL1971592T3 (de)
WO (3) WO2007119116A2 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1856087A1 (de) 2005-03-08 2007-11-21 Teva Pharmaceutical Industries Limited Kristallformen von (s)-(+)-n,n-dimethyl-3-(1-naphthalenyloxy)-3-(2-thienyl) propanamin-oxalat und deren herstellung
CA2599478A1 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the purification of duloxetine hydrochloride
EP1838692A2 (de) 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleat und herstellungsverfahren dafür
US7759500B2 (en) 2005-12-05 2010-07-20 Teva Pharmaceutical Industries Ltd. 2-(N-methyl-propanamine)-3-(2-naphthol)thiophene, an impurity of duloxetine hydrochloride
PL1971592T3 (pl) 2005-12-12 2011-09-30 Medichem Sa Ulepszona synteza i preparaty soli duloksetyny
WO2007098250A2 (en) 2006-02-21 2007-08-30 Teva Pharmaceutical Industries Ltd. Process for the preparation of (s)-(-)-n,n-dimethyl-3-(2-thienyl)-3-hydroxypropanamine, a duloxetine intermediate
HU228458B1 (en) 2006-03-13 2013-03-28 Egis Gyogyszergyar Nyrt Duloxetine salts for producing pharmaceutical compositions
EP2016066A4 (de) * 2006-05-10 2010-11-24 Reddys Lab Ltd Dr Verfahren zur herstellung von duloxetin
WO2009019719A2 (en) * 2007-08-09 2009-02-12 Ind-Swift Laboratories Limited Process for the preparation of 3-aryloxy-3-arylpropanamines
EP2107057A1 (de) 2008-04-04 2009-10-07 Ranbaxy Laboratories Limited Verfahren zur Herstellung von reinem Duloxetin
WO2011092065A1 (en) * 2010-01-29 2011-08-04 Nicox S.A. Nitric oxide releasing compounds for the treatment of neurophatic pain
CN103896910B (zh) * 2012-12-27 2016-02-03 成都国弘医药有限公司 一种度洛西汀的合成方法
CN103524480B (zh) * 2013-10-21 2016-04-20 山东鲁药制药有限公司 一种盐酸度洛西汀的制备方法
CN104478849A (zh) * 2014-02-14 2015-04-01 广东东阳光药业有限公司 制备去甲肾上腺素再摄取双重抑制剂的方法
JP2016172704A (ja) * 2015-03-17 2016-09-29 株式会社トクヤマ デュロキセチン塩酸塩の製造方法、及び新規な結晶構造のデュロキセチン塩酸塩
CN107382958B (zh) * 2017-07-05 2021-11-09 浙江华海药业股份有限公司 一种度洛西汀中间体的结晶方法
EP4633614A1 (de) * 2022-12-17 2025-10-22 Sun Pharmaceutical Industries Limited Stabile pharmazeutische zusammensetzung eines amin-arzneimittels

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4956388A (en) 1986-12-22 1990-09-11 Eli Lilly And Company 3-aryloxy-3-substituted propanamines
HU9202128D0 (en) 1992-06-26 1992-10-28 Richter Gedeon Vegyeszet Method for producing n-methyl-(3-phenyl-3-(4-[trifluoro-methyl])-phenooxi-)-amine
US5362886A (en) * 1993-10-12 1994-11-08 Eli Lilly And Company Asymmetric synthesis
CA2362185C (en) 1999-04-09 2009-06-02 Eli Lilly And Company Methods for preparing 3-aryloxy-3-arylpropylamines and intermediates thereof
WO2004026226A2 (en) * 2002-05-10 2004-04-01 Cytokinetics, Inc. Compounds, compositions and methods
PL374993A1 (en) * 2002-08-06 2005-11-14 Teva Pharmaceutical Industries Ltd. Novel crystalline forms of gatifloxacin
GB0229583D0 (en) * 2002-12-19 2003-01-22 Cipla Ltd A process for preparing duloxetine and intermediates for use therein
GB0410470D0 (en) * 2004-05-11 2004-06-16 Cipla Ltd Pharmaceutical compound and polymorphs thereof
WO2006027798A2 (en) 2004-08-05 2006-03-16 Sun Pharmaceutical Industries Limited A process for preparation of an antidepressant compound
CZ297560B6 (cs) 2004-10-26 2007-02-07 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu (duloxetinu)
WO2006071868A2 (en) 2004-12-23 2006-07-06 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
CA2599478A1 (en) 2005-03-14 2006-09-21 Teva Pharmaceutical Industries Ltd. Process for the purification of duloxetine hydrochloride
EP1838692A2 (de) 2005-09-22 2007-10-03 Teva Pharmaceutical Industries Ltd Dnt-maleat und herstellungsverfahren dafür
PL1971592T3 (pl) 2005-12-12 2011-09-30 Medichem Sa Ulepszona synteza i preparaty soli duloksetyny
CZ299270B6 (cs) * 2006-01-04 2008-06-04 Zentiva, A. S. Zpusob výroby hydrochloridu (S)-N-methyl-3-(1-naftyloxy)-3-(2-thienyl)propylaminu

Also Published As

Publication number Publication date
US20090093645A1 (en) 2009-04-09
WO2007119114A2 (en) 2007-10-25
WO2007096707A3 (en) 2008-01-24
WO2007119116A3 (en) 2008-01-31
DE602006021628D1 (de) 2011-06-09
WO2007096707A2 (en) 2007-08-30
US20090221668A1 (en) 2009-09-03
WO2007119116A2 (en) 2007-10-25
PL1971592T3 (pl) 2011-09-30
EP1971593A2 (de) 2008-09-24
EP1971592A2 (de) 2008-09-24
US20090182156A1 (en) 2009-07-16
AR058321A1 (es) 2008-01-30
CA2634007A1 (en) 2007-08-30
IL192114A0 (en) 2009-08-03
EP1971591A2 (de) 2008-09-24
US20100286412A1 (en) 2010-11-11
CA2634008A1 (en) 2007-10-25
IL192116A0 (en) 2009-08-03
CA2634009A1 (en) 2007-10-25
WO2007119114A3 (en) 2008-01-24
US8158808B2 (en) 2012-04-17
IL192115A0 (en) 2009-08-03
EP1971592B1 (de) 2011-04-27

Similar Documents

Publication Publication Date Title
IL192116A0 (en) Improved synthesis and preparations of duloxetine salts
DE602006012450D1 (de) Exo- und diastereoselektive synthese von himbacin-analoga
DE60313289D1 (de) Kontrollierte synthese von ziprasidon
EP2035001A4 (de) Stabile laquinimod-zubereitungen
EP1943338A4 (de) Zellfreie synthese membrangebundener polypeptide
ATE365169T1 (de) Regioselektive synthese von cci-779
CY2017048I1 (el) Νεες φαρμακευτικες χρησεις των παραγωγων σταυροσπορινης
DK1913001T3 (da) (r)-n-methylnaltrexon, fremgangsmåder til syntese og farmaceutisk anvendelse heraf
EP1848778A4 (de) Neusynthese von bakteriochlorinen
DE602006004463D1 (de) Kristallform von asenapinmaleat
ATE472527T1 (de) Synthese und verwendungen von 2-oxo-4- methylthiobuttersäure, deren salze und deren derivate
DE602005005941D1 (de) Monohydrochloridsalz von 1-Ä3-Ä3-(4-Chlorophenyl)propoxyÜpropylÜ-piperidin
EP1957474A4 (de) Synthese von ftsz-hemmern
EP1863800A4 (de) Synthese von avrainvillamid, stephacidin b und analoga davon
ATE500249T1 (de) Synthese von himbacinanaloga
DE602006004713D1 (de) Trifluormethylbenzamidderivate und therapeutische verwendungen dafür
EP1885919A4 (de) Methylierung und expression von genen
ATE405326T1 (de) Kosmetiktuchprodukt
EP1916313A4 (de) Sprinklerkopf
ATE497504T1 (de) Aminoderivate von b-homoandrostanen und b- heteroandrostanen
DE602006013028D1 (de) Lösungsphasensynthese von leuprolid und dessen zwischenprodukten
DE602005020603D1 (de) Synthese von trithiocarbonat-raft-agentia und zwischenprodukte daraus
DE602005025521D1 (de) Synthese von aminosäure-n-carboxyanhydriden
ATE459627T1 (de) Synthesen und herstellungen von narwedin und verwandten neuen verbindungen
ATE402145T1 (de) Synthese von pyrrol-2-carbonsäurenitrilen

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties